1 day Ago By Defense World Staff
Renaissance Technologies LLC raised its stake in shares of TELA Bio, Inc. (NASDAQ:TELA – Free Report) by 185.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The firm owned 425,140 shares of the company’s stock after buying an additional 276,240 shares during the quarter. Renaissance Technologies LLC owned about 1.08% of TELA Bio worth $1,284,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of TELA. Prudential Financial Inc. bought a new position in shares of TELA Bio during the 4th quarter valued at about $57,000.
Commonwealth Equity Services LLC lifted its stake in TELA Bio by 91.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 28,441 shares of the company’s stock valued at $86,000 after buying an additional 13,555 shares in the last quarter.
Diametric Capital LP bought a new position in TELA Bio in the fourth quarter valued at approximately $108,000. JPMorgan Chase & Co. boosted its holdings in shares of TELA Bio by 39,329.
5% in the fourth quarter. JPMorgan Chase & Co. now owns 133,666 shares of the company’s stock valued at $404,000 after buying an additional 133,327 shares during the period.
Finally, Geode Capital Management LLC increased its position in shares of TELA Bio by 78.4% during the fourth quarter. Geode Capital Management LLC now owns 311,405 shares of the company’s stock worth $941,000 after acquiring an additional 136,890 shares in the last quarter.
94.35% of the stock is owned by institutional investors. TELA Bio Price PerformanceShares of NASDAQ TELA opened at $0.
94 on Wednesday. The company has a debt-to-equity ratio of 14.22, a current ratio of 2.
62 and a quick ratio of 1.81. The business has a 50-day moving average of $1.
62 and a 200-day moving average of $2.40. The stock has a market capitalization of $37.
19 million, a price-to-earnings ratio of -0.56 and a beta of 0.98.
TELA Bio, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $6.
50. TELA Bio (NASDAQ:TELA – Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.
23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01.
TELA Bio had a negative return on equity of 556.18% and a negative net margin of 60.49%.
The firm had revenue of $17.65 million during the quarter, compared to the consensus estimate of $23.17 million.
As a group, sell-side analysts predict that TELA Bio, Inc. will post -1.37 earnings per share for the current fiscal year.
Analysts Set New Price TargetsTELA has been the topic of a number of research reports. Piper Sandler lowered TELA Bio from an “overweight” rating to a “neutral” rating and cut their price target for the company from $5.00 to $2.
00 in a report on Friday, March 21st. Canaccord Genuity Group cut their target price on TELA Bio from $12.00 to $7.
00 and set a “buy” rating on the stock in a research note on Friday, March 21st.Check Out Our Latest Stock Analysis on TELATELA Bio Company Profile (Free Report)TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Recommended StoriesFive stocks we like better than TELA BioWhat Investors Need to Know About Upcoming IPOsDon’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetHow to Invest in the FAANG StocksCoca-Cola Company Stock Can Bubble to New Highs This YearHow to Use the MarketBeat Excel Dividend Calculator3 Stocks Lifting 2025 Guidance Despite Market JittersWant to see what other hedge funds are holding TELA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TELA Bio, Inc. (NASDAQ:TELA – Free Report).
.
